S&P 500   2,966.15 (-0.14%)
DOW   26,787.36 (-0.11%)
QQQ   191.09 (-0.01%)
AAPL   235.87 (-0.14%)
FB   183.28 (-0.49%)
MSFT   139.55 (-0.09%)
GOOGL   1,217.77 (+0.17%)
AMZN   1,736.43 (+0.26%)
CGC   18.86 (-2.93%)
NVDA   186.53 (+0.29%)
MU   44.86 (-0.53%)
BABA   171.16 (-1.03%)
GE   8.72 (-0.91%)
TSLA   256.96 (+3.66%)
AMD   30.53 (+2.62%)
T   37.47 (-0.29%)
F   8.82 (+0.46%)
ACB   3.51 (-4.62%)
PRI   121.47 (-0.18%)
NFLX   285.53 (+0.92%)
BAC   29.14 (+0.80%)
GILD   64.51 (+0.81%)
DIS   129.70 (-0.25%)
S&P 500   2,966.15 (-0.14%)
DOW   26,787.36 (-0.11%)
QQQ   191.09 (-0.01%)
AAPL   235.87 (-0.14%)
FB   183.28 (-0.49%)
MSFT   139.55 (-0.09%)
GOOGL   1,217.77 (+0.17%)
AMZN   1,736.43 (+0.26%)
CGC   18.86 (-2.93%)
NVDA   186.53 (+0.29%)
MU   44.86 (-0.53%)
BABA   171.16 (-1.03%)
GE   8.72 (-0.91%)
TSLA   256.96 (+3.66%)
AMD   30.53 (+2.62%)
T   37.47 (-0.29%)
F   8.82 (+0.46%)
ACB   3.51 (-4.62%)
PRI   121.47 (-0.18%)
NFLX   285.53 (+0.92%)
BAC   29.14 (+0.80%)
GILD   64.51 (+0.81%)
DIS   129.70 (-0.25%)
Log in

ENDRA Life Sciences Stock Price, News & Analysis (NASDAQ:NDRA)

$1.12
-0.03 (-2.61 %)
(As of 10/14/2019 04:00 PM ET)
Today's Range
$1.11
Now: $1.12
$1.17
50-Day Range
$1.01
MA: $1.47
$1.86
52-Week Range
$0.90
Now: $1.12
$5.75
Volume29,442 shs
Average Volume184,257 shs
Market Capitalization$7.43 million
P/E RatioN/A
Dividend YieldN/A
Beta1.24
ENDRA Life Sciences Inc. develops medical imaging technology based on the thermos-acoustic effect that improves the sensitivity and specificity of clinical ultrasound. It offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. It also offers Nexus-128 system that combines light-based thermos-acoustics and ultrasound to address the imaging needs of researchers studying disease models in pre-clinical applications. ENDRA Life Sciences Inc. has collaborative research agreement with General Electric Company. The company was incorporated in 2007 and is based in Ann Arbor, Michigan.

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NDRA
CUSIPN/A
Phone734-335-0468

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10,000.00
Book Value$0.94 per share

Profitability

Net Income$-9,800,000.00

Miscellaneous

Employees11
Market Cap$7.43 million
Next Earnings Date11/4/2019 (Estimated)
OptionableNot Optionable

Receive NDRA News and Ratings via Email

Sign-up to receive the latest news and ratings for NDRA and its competitors with MarketBeat's FREE daily newsletter.


ENDRA Life Sciences (NASDAQ:NDRA) Frequently Asked Questions

What is ENDRA Life Sciences' stock symbol?

ENDRA Life Sciences trades on the NASDAQ under the ticker symbol "NDRA."

How were ENDRA Life Sciences' earnings last quarter?

ENDRA Life Sciences Inc (NASDAQ:NDRA) released its earnings results on Thursday, August, 8th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by $0.03. View ENDRA Life Sciences' Earnings History.

When is ENDRA Life Sciences' next earnings date?

ENDRA Life Sciences is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for ENDRA Life Sciences.

What price target have analysts set for NDRA?

3 brokers have issued 12 month target prices for ENDRA Life Sciences' stock. Their predictions range from $6.00 to $6.00. On average, they anticipate ENDRA Life Sciences' stock price to reach $6.00 in the next year. This suggests a possible upside of 435.7% from the stock's current price. View Analyst Price Targets for ENDRA Life Sciences.

What is the consensus analysts' recommendation for ENDRA Life Sciences?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ENDRA Life Sciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ENDRA Life Sciences.

Has ENDRA Life Sciences been receiving favorable news coverage?

Media headlines about NDRA stock have been trending negative this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ENDRA Life Sciences earned a coverage optimism score of -2.4 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for ENDRA Life Sciences.

Are investors shorting ENDRA Life Sciences?

ENDRA Life Sciences saw a decrease in short interest in September. As of September 30th, there was short interest totalling 770,400 shares, a decrease of 7.7% from the August 30th total of 834,500 shares. Based on an average trading volume of 77,400 shares, the short-interest ratio is presently 10.0 days. Approximately 10.9% of the company's shares are sold short. View ENDRA Life Sciences' Current Options Chain.

Who are some of ENDRA Life Sciences' key competitors?

What other stocks do shareholders of ENDRA Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ENDRA Life Sciences investors own include Vericel (VCEL), Amarin (AMRN), Aptose Biosciences (APTO), Seanergy Maritime (SHIP), Achieve Life Sciences (ACHV), AcelRx Pharmaceuticals (ACRX), Adverum Biotechnologies (ADVM), Atomera (ATOM), Aurinia Pharmaceuticals (AUPH) and AzurRx BioPharma (AZRX).

Who are ENDRA Life Sciences' key executives?

ENDRA Life Sciences' management team includes the folowing people:
  • Mr. Francois Michelon, Chairman & CEO (Age 53)
  • Mr. David R. Wells, CFO & Sec. (Age 57)
  • Mr. Michael Thornton, Chief Technology Officer (Age 51)
  • Dr. Jonathan Behr Ph.D., Co-Founder
  • Mr. Steve Freeman, HR Leader

When did ENDRA Life Sciences IPO?

(NDRA) raised $10 million in an initial public offering on Friday, February 3rd 2017. The company issued 2,000,000 shares at a price of $5.00-$5.50 per share. Dougherty & Company and Dawson James Securities acted as the underwriters for the IPO.

How do I buy shares of ENDRA Life Sciences?

Shares of NDRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is ENDRA Life Sciences' stock price today?

One share of NDRA stock can currently be purchased for approximately $1.12.

How big of a company is ENDRA Life Sciences?

ENDRA Life Sciences has a market capitalization of $7.43 million and generates $10,000.00 in revenue each year. The company earns $-9,800,000.00 in net income (profit) each year or ($2.10) on an earnings per share basis. ENDRA Life Sciences employs 11 workers across the globe.View Additional Information About ENDRA Life Sciences.

What is ENDRA Life Sciences' official website?

The official website for ENDRA Life Sciences is http://www.endrainc.com/.

How can I contact ENDRA Life Sciences?

ENDRA Life Sciences' mailing address is 3600 GREEN COURT SUITE 350, ANN ARBOR MI, 48105. The company can be reached via phone at 734-335-0468 or via email at [email protected]


MarketBeat Community Rating for ENDRA Life Sciences (NASDAQ NDRA)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  171 (Vote Outperform)
Underperform Votes:  201 (Vote Underperform)
Total Votes:  372
MarketBeat's community ratings are surveys of what our community members think about ENDRA Life Sciences and other stocks. Vote "Outperform" if you believe NDRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NDRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel